Shannon has served as our Vice President of Regulatory Affairs and Quality since 2018. Shannon has over 20 years of research and drug development experience with over 15 years as a leader in regulatory affairs. Shannon began her career through a drug development fellowship with Cato Research, a specialty contract research organization, and then transitioned into medical writing and regulatory affairs specializing in neurology and oncology product development from nonclinical studies through marketing approval. In 2010, Shannon moved to Pearl Therapeutics to focus on inhaled respiratory drug products, drug-device combination products, and product development through the US 505(b)(2) approval pathway. In addition to her regulatory leadership at Pearl, Shannon provided key inputs to Pearl’s nonclinical and clinical programs. Pearl Therapeutics received the FierceBiotech 2011 Fierce 15 award and was acquired by AstraZeneca in 2013 for $1.15 billion. Shannon has led global regulatory strategy programs including regulatory health authority interactions and approval of multiple new drug applications, including most recently approvals of Bevespi Aerosphere® and Breztri®. Shannon received a B.S. in biology from Duke University and holds a PhD in pharmacology from the University of North Carolina at Chapel Hill.